Skip to content
naulon

Not checkedNot checked for notices yet.

Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe

Linda A. Mandikiyana Chirimuta, Margaret J. Pascoe, Sara Lowe

Southern African Journal of HIV Medicine · 2022

doi:10.4102/sajhivmed.v23i1.1435 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

We report two cases of dolutegravir (DTG) resistance in highly treatment experienced patients. Monitoring for treatment failure and adherence support is important in highly treatment experienced patients taking DTG. What this study adds: Dolutegravir is the mainstay of HIV treatment programmes and emergence of drug resistance to DTG is of public health relevance.

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.